Method for reducing adenosine levels with a dehydroepiandrostero

Details Method for reducing adenosine levels with a dehydroepiandrostero Method for reducing adenosine levels with a dehydroepiandrostero

1997-05-22

2000-07-11

Harrison, Robert H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514688, 514826, A61K 3156

Patent

active

060873515

ABSTRACT:
A method and composition for reducing adenosine levels comprises administering a dehydroepiandrosterone, and optionally a ubiquinone.

REFERENCES:
patent: 4393066 (1983-07-01), Garrett et al.
patent: 4499064 (1985-02-01), Shive
patent: 4575498 (1986-03-01), Holmes et al.
patent: 4628052 (1986-12-01), Peat
patent: 4920115 (1990-04-01), Nestler et al.
patent: 4931441 (1990-06-01), Lawrence
patent: 4985443 (1991-01-01), Montes
patent: 5021417 (1991-06-01), Prost
patent: 5059595 (1991-10-01), Le Grazie
patent: 5077284 (1991-12-01), Loria et al.
patent: 5110810 (1992-05-01), Eich et al.
patent: 5118505 (1992-06-01), Koltringer
patent: 5162198 (1992-11-01), Eich et al.
patent: 5173488 (1992-12-01), Haeger
patent: 5177076 (1993-01-01), Nijkerk et al.
patent: 5266312 (1993-11-01), Leung et al.
patent: 5270305 (1993-12-01), Palmer
patent: 5347005 (1994-09-01), Mueller et al.
patent: 5407684 (1995-04-01), Loria et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5489581 (1996-02-01), Daynes et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5538734 (1996-07-01), Le Grazie
patent: 5583126 (1996-12-01), Daynes et al.
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5811418 (1998-09-01), Daynes et al.
patent: 5948434 (1999-09-01), Labrie
Itagaki et al.; "Effect of Cortisol on the Release of Human Decidual"; Caplus, 114875 (1991), Abstract.
Lejeune; "Pathogenesis of Mental Impairment in Trisomy 21"; Biosis, 92:27643 (1996) Abstract.
Peeters et al.; "Differences in Purine Metabolism in Patients with Down's Syndrome"; Biosis, 97125039 (1996) Abstract.
Mileva et al.; "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients"; 07608054 (1990) Abstract.
Feher et al.; "Adrenocortical Function in Bronchial Asthma"; 05219963 (1983) Abstract.
Koo et al.; "Experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma"; Biosis, 85019995 (1987) Abstract.
Sur et al.; "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma"; Annals of Allergy, 70:147-152 (1993).
Rowe et al.; "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis"; Amer J. of Emergency Medicine, 10(4):301-310 (1992).
Van de Graaf et al.; "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids"; Bronchial Asthma and Respiratory Membrane Permeability, 143:362-368 (1991).
Hummel et al.; "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma"; The Lancet, 340(8834/8835); 1483-1487 (1992).
Dompeling et al.; "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique"; Family Practice--An International Journal, pp. 161-166 (1992).
Coleridge et al.; "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators"; Medicine, 23:348-354 (1993).
Dworski et al.; "Conspectus: Inhaled Steroids in Asthma"; Comprehensive Therapy, 18:3 (1992).
C. Reed; "Aerosol Steroids as Primary Treatment of Mild Asthma"; The New England J. of Med., 325(6):425-426 (1991).
Sonka et al. Gout and Dehydroepiandrosterone. 3. DHEA Administration. Endokrynol-Pol. 24(3): pp. 209-218. May-Jun. 1973. Medline Citation Only.
Holzmann et al. Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg. Weekly. Arch-Dermatol-Forsch. 247(1):pp. 23-28 (1973). Citation Only.
Sasaki et al. Cervical Ripening with Dehydroepiandrosterone Sulphate. Br-J Obstet-Gynaecol. 89(3): pp. 195-198. Mar. 1982, Medline Citation Only.
Pashko et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice. Cancer Res. 45(1):164-6.
Araneo et al. Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury. J-Surg-Res. 59(2): pp. 250-262. Aug. 1995. Medline Citation Only.
Van-Vollenhoven et al. DHEA in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Arthritis-Rheum. 38(12): pp. 1826-1831. Dec. 1995. Medline Citation Only.
Wolkowitz et al. DHEA Treatment of Depression. Biol-Psychiatry. 41(3): pp. 311-318. Feb. 1, 1997. Medline Citation Only.
Shomali.M.E. The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies. Md-Med-J. 46(4):181-6. Cit.
Koo et al.; "Experiences with DHEA Therapy in Steroid-Dependent Intrinsic Bronchical Asthma"; Orvosi Hetilap; 128(38) pp. 1995-1997, 1987.

Affiliated with

Also associated with

Rating

Method for reducing adenosine levels with a dehydroepiandrostero does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for reducing adenosine levels with a dehydroepiandrostero, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing adenosine levels with a dehydroepiandrostero will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-542594